FGF21 and obesity due to melanocortin 4 receptor deficiency: Pharmaceutical administration of recombinant FGF21 protein or FGF21 mimetics is expected to improve obesity, obesity-associated hyperglycaemia, and hyperlipidaemia3, 4.